Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid in osteonecrosis of the hip
NCT00781261Phase 2Unknown
- Sponsor
- University of Sydney
- Start
- Aug 2009
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zoledronic acid in osteonecrosis of the hip, sponsored by University of Sydney. Primary endpoint: Pain and disability in the hip at 1 year. Status: unknown.
02
Drugs
zoledronic acid
03
Conditions
osteonecrosis of the hip
Beyond the preview
Go deeper on NCT00781261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781261.